All In Biotech

Drug Trial Radar · NCT06868264

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects With Chronic Hepatitis C Virus (HCV) Infection

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 940 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

940

Actual

Start

Apr 7, 2025

Primary completion

Jun 18, 2026

Study completion Sep 9, 2026

Sponsor

Lead sponsor
Atea Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.

Conditions

  • HEPATITIS C VIRUS CHRONIC INFECTION

Interventions

  • Bemnifosbuvir-Ruzasvir (BEM/RZR)Drug

    BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)

  • Sofosbuvir-Velpatasvir (SOF/VEL)Drug

    SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.Time frame: Day 1 through Week 24

Locations

105 sites in 2 countries. Site status is shown where the registry gives one.

  • Atea Study Site

    Birmingham, Alabama

  • Atea Study Site

    Dothan, Alabama

  • Atea Study Site

    Chandler, Arizona

  • Atea Study Site

    Flagstaff, Arizona

  • Atea Study Site

    Mesa, Arizona

  • Atea Study Site

    Phoenix, Arizona

  • Atea Study Site

    Phoenix, Arizona

  • Atea Study Site

    Tucson, Arizona

  • Atea Study Site

    Little Rock, Arkansas

  • Atea Study Site

    Bakersfield, California

  • Atea Study Site

    Coronado, California

  • Atea Study Site

    Escondido, California

  • Atea Study Site

    Fresno, California

  • Atea Study Site

    Long Beach, California

  • Atea Study Site

    Los Angeles, California

  • Atea Study Site

    Los Angeles, California

  • Atea Study Site

    Orange, California

  • Atea Study Site

    Pasadena, California

  • Atea Study Site

    Sacramento, California

  • Atea Study Site

    Torrance, California

  • Atea Study Site

    Valencia, California

  • Atea Study Site

    Colorado Springs, Colorado

  • Atea Study Site

    Washington D.C., District of Columbia

  • Atea Study Site

    Washington D.C., District of Columbia

  • Atea Study Site

    Coral Gables, Florida

  • Atea Study Site

    DeLand, Florida

  • Atea Study Site

    Fort Lauderdale, Florida

  • Atea Study Site

    Ft. Pierce, Florida

  • Atea Study Site

    Gainesville, Florida

  • Atea Study Site

    Inverness, Florida

  • Atea Study Site

    Jupiter, Florida

  • Atea Study Site

    Lauderdale Lakes, Florida

  • Atea Study Site

    Maitland, Florida

  • Atea Study Site

    Miami, Florida

  • Atea Study Site

    Miami Lakes, Florida

  • Atea Study Site

    Orlando, Florida

  • Atea Study Site

    Pembroke Pines, Florida

  • Atea Study Site

    Sarasota, Florida

  • Atea Study Site

    West Palm Beach, Florida

  • Atea Study Site

    Macon, Georgia

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.